<a href="https://www.fiercebiotech.com/biotech/affibody-gets-izokibep-back-track-while-seeking-new-home-after-acelyrin-rejection" hreflang="en">Affibody gets izokibep ‘back on track’ while seeking ‘new home’ after drug’s Acelyrin rejection</a>
Affibody is showcasing the potential of its inflammation drug izokibep after regaining rights from Acelyrin, which faced challenges during its merger. The company is seeking new partnerships while prioritizing its oncology projects, despite izokibep's promising clinical data in treating psoriatic arthritis and hidradenitis suppurativa.
Affibody's izokibep, regaining momentum after being returned by Acelyrin, demonstrates significant potential in treating inflammatory diseases like psoriatic arthritis and hidradenitis suppurativa, evidenced by promising clinical data presented at EULAR. This positions izokibep as an attractive acquisition target for companies focused on immunology, offering an opportunity for collaboration or investment in a late-stage asset with a clear path towards regulatory submission.